Stay updated on Talimogene Laherparepvec and Nivolumab Combination Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec and Nivolumab Combination Clinical Trial page.

Latest updates to the Talimogene Laherparepvec and Nivolumab Combination Clinical Trial page
- Check2 days agoChange DetectedNo additions or deletions were recorded. The page content remains unchanged relative to the provided data.SummaryDifference0.1%

- Check9 days agoChange DetectedA new Sample Collection section has been added. The study protocol has been updated to version 3.5.4, replacing the prior 3.5.3 revision.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision label was updated from v3.5.2 to v3.5.3, indicating a minor update to the page version.SummaryDifference0.0%

- Check39 days agoChange DetectedAdded revision entries for v3.5.2 on 2026-04-09 and 2026-04-13. Removed revision entry for v3.5.0 on 2026-04-07 and 2026-04-08.SummaryDifference0.2%

- Check46 days agoChange DetectedTwo new entries were added to the study record on 2026-04-07 and 2026-04-08, and two entries were removed on 2026-03-31 and 2026-04-01.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Eccrine porocarcinoma and Cutaneous neuroendocrine carcinoma to the inclusion criteria; two other tumor types were removed on 2026-03-24 and 2026-03-25.SummaryDifference0.2%

Stay in the know with updates to Talimogene Laherparepvec and Nivolumab Combination Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec and Nivolumab Combination Clinical Trial page.